Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2020-07-23 Earnings Release
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro providing a business update and financial information for the second quarter of 2020. It includes details on cash position, clinical trial progress, and management changes. While it contains financial data, it is a periodic update rather than a full quarterly report (IR) or a formal earnings release (ER) that typically accompanies a full set of financial statements. Given the nature of the document as a summary of quarterly business and financial highlights, it fits best under the 'Earnings Release' (ER) category as it serves the function of announcing quarterly financial status and operational updates to the market. Q2 2020
2020-07-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'information financière et point d'activité du 2ème trimestre 2020'. It provides a summary of financial highlights (cash position, cash burn), operational updates (clinical trial progress, management changes), and upcoming financial events. It is an initial announcement of quarterly financial results and business highlights, which fits the definition of an Earnings Release (ER). It is not a full quarterly report (IR) as it is a press release summary, and it is not an RPA because it contains the actual financial data and business updates rather than just announcing the availability of a report. Q2 2020
2020-07-23 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the publication of scientific research in the journal 'Science Advances'. It describes the findings of a study and its implications for the company's research pipeline. It does not constitute a formal financial report (10-K, IR), a regulatory filing, or a specific corporate event announcement like a dividend or board change. As it is a general corporate announcement regarding research progress, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2020-07-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro announcing the publication of scientific research data in the journal 'Science Advances'. It describes the findings of a study regarding human endogenous retroviral proteins and their link to psychotic disorders. As this is a general corporate announcement regarding research developments rather than a formal financial report, a regulatory filing, or a specific investor presentation, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements.
2020-07-21 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the enrollment of the first patient in a Phase 2 clinical trial for a drug candidate (temelimab). It does not report financial results, dividends, or governance changes, nor is it a formal regulatory filing or a report publication announcement. As it is a general corporate announcement regarding operational/clinical progress that does not fit into the specific categories provided, it falls under the fallback category of Regulatory Filings (RNS).
2020-06-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the recruitment of the first patient in a Phase 2 clinical trial. It provides details about the trial's purpose, the collaboration with the Karolinska Institutet, and the impact of COVID-19 on the timeline. As this is a general corporate announcement regarding operational progress (clinical trials) that does not fit into specific financial reporting categories like 10-K, ER, or IR, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2020-06-25 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.